Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

834.45 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
From argenx SE
Via GlobeNewswire
News headline image
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
News headline image
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx announces closing of global offering
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
From argenx SE
Via GlobeNewswire
News headline image
argenx announces full exercise of underwriters’ option to purchase additional ADSs
From argenx SE
Via GlobeNewswire
News headline image
argenx raises $1.1 billion in gross proceeds in a global offering
From argenx SE
Via GlobeNewswire
News headline image
argenx announces launch of proposed global offering
From argenx SE
Via GlobeNewswire
argenx SE (NASDAQ: ARGX) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From Zai Lab Limited
Via GlobeNewswire
News headline image
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
News headline image
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire
News headline image
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via GlobeNewswire
News headline image
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx announces results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at BofA Securities 2023 Health Care Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
From argenx SE
Via GlobeNewswire
News headline image
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
From argenx SE
Via GlobeNewswire
News headline image
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.